Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRIT 2
ISRCTN54923521Phase 3Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Jun 2008
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of imatinib and dasatinib in chronic myelogenous leukemia (CML), sponsored by Newcastle Hospitals NHS Foundation Trust. Started Jun 2008; status: completed.
02
Drugs
imatinibdasatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ISRCTN54923521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN54923521.